Multiple Myeloma – Landscape & Forecast – Disease Landscape & Forecast
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment durations. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Darzalex-based therapies, is impacting the disease’s treatment algorithm. Although Bristol Myers Squibb’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of treatment, recently approved therapies (GlaxoSmithKline’s Blenrep and Sanofi’s Sarclisa) have expanded the number of options available. CAR T-cell therapies (Bristol Myers Squibb / Bluebird Bio’s Abecma and Janssen’s Carvykti) and the anti-BCMA bispecific agents (Pfizer’s elranatamab and Janssen’s teclistamab) are also expected to compete fiercely, in addition to AbbVie / Roche’s Venclexta / Venclyxto. Nevertheless, immense clinical and commercial potential remains for multiple myeloma therapies with improved efficacy, a novel mechanism of action, and/or the ability to treat underserved patient segments, such as smoldering multiple myeloma.
Questions answered
- What is the size of the drug-treatable multiple myeloma population, and how do the drug-treatment rates vary by geography, line of therapy, and over time?
- How will the use of Revlimid and Velcade change over the forecast period, and what impact will generic entry have on the multiple myeloma market?
- What are thought leaders’ opinions of anti-BCMA agents that are approved or in Phase II / III development, such as the BCMA-targeting antibody-drug conjugate Blenrep, the CAR T-cell therapies Abecma and Carvykti, and the bispecific agents elranatamab and teclistamab?
- What are the drivers of, and constraints on, the multiple myeloma therapy market?
- How will the entry of new agents shape this market?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Scope
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with thought-leading hematologist-oncologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Incidence of multiple myeloma by country, segmented by line of therapy and by symptomatic status.
Emerging therapies: Phase III/PR: 3 drugs; coverage of select Phase I and II products.
Table of contents
- Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast
- Key updates
- Q2 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2021
- December 2021
- Q3 2021
- September 2021
- Q2 2021
- June 2021
- May 2021
- April 2021
- Q2 2022
- Key findings
- Multiple Myeloma - Key findings
- June 2021
- May 2021
- April 2021
- Multiple Myeloma - Key findings
- Market Outlook
- Key Findings
- Major-Market Share of Drug Classes for Multiple Myeloma: 2020
- Major-Market Share of Drug Classes for Multiple Myeloma: 2030
- Major-Market Sales of Key Drugs in the Multiple Myeloma Market: 2020-2030
- Major-Market Multiple Myeloma Sales by Line of Therapy: 2020-2030
- Drug-Treatable Population Share and Major-Market Sales Share in Multiple Myeloma: 2020
- Drug-Treatable Population Share and Major-Market Sales Share in Multiple Myeloma: 2030
- Population Positioning of Therapies in Multiple Myeloma
- Multiple Myeloma SWOT Analysis
- Market Drivers and Constraints
- What Factors Are Driving the Market for Multiple Myeloma?
- What Factors Are Constraining the Market for Multiple Myeloma?
- Segment-Specific Trends
- Smoldering Multiple Myeloma
- First-Line Transplant-Eligible Multiple Myeloma
- Patient-Share Dynamics of Key Regimens in First-Line Transplant-Eligible Multiple Myeloma in the United States: 2020-2030
- First-Line Transplant-Ineligible Multiple Myeloma
- Patient-Share Dynamics of Key Regimens in First-Line Transplant-Ineligible Multiple Myeloma in the United States: 2020-2030
- Relapsed / Refractory Multiple Myeloma
- Patient-Share Dynamics of Key Regimens in Second-Line Multiple Myeloma in the United States: 2020-2030
- Patient-Share Dynamics of Key Regimens in Third-Line Multiple Myeloma in the United States: 2020-2030
- Patient-Share Dynamics of Key Regimens in Fourth-Line Multiple Myeloma in the United States: 2020-2030
- Patient-Share Dynamics of Key Regimens in Fifth- to Seventh-Line Multiple Myeloma in the United States: 2020-2030
- Key Findings
- Forecast
- Market Forecast Downloads
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease Overview
- Clinical Manifestations of Multiple Myeloma
- Disease Pathophysiology
- Overview
- Plasma Cell and Myeloma Cell Process
- Risk Factors
- Select Risk Factors Associated With Multiple Myeloma
- Staging and Classification
- Classification of Multiple Myeloma
- Revised IMWG Classification Criteria of Select Plasma Cell Disorders
- Staging of Multiple Myeloma
- Durie-Salmon Staging System for Multiple Myeloma
- International Staging System for Multiple Myeloma
- Key Pathways and Drug Targets
- Drug Targets and Potential Therapies for Multiple Myeloma
- IMiD-Mediated Disruption of Myeloma Cell-Microenvironment Interactions
- Potentially Synergistic Antitumor Effects of Proteasome and Aggresome Pathways
- Biology of Selective Inhibitors of Nuclear Export (SINE)
- Biology of B-Cell Maturation Antigen (BCMA)
- Aminopeptidases in Apoptosis of Myeloma Cells
- Disease Overview
- Epidemiology
- Key Findings
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Diagnosed Incidence of Multiple Myeloma
- Diagnosed Incident Cases of Multiple Myeloma: 2020-2030
- Disease Definition
- Methods
- Sources Used for Symptomatic Distribution of Multiple Myeloma
- Diagnosed Incident Cases of Multiple Myeloma by Symptoms: 2020-2030
- Disease Definition
- Methods
- Sources Used for Asymptomaticu00a0Multiple Myelomau00a0Progression to Symptomatic Multiple Myeloma
- Asymptomatic Cases Progressing to Symptomatic Cases of Multiple Myeloma in the Major Pharmaceutical Markets: 2020-2030
- Drug-Treatable Cases of Multiple Myeloma: 2020-2030
- Multiple Myeloma Patient Flow
- Drug-Treated Cases of Multiple Myeloma: 2020-2030
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for multiple myeloma
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for multiple myeloma
- Current treatments used for multiple myeloma
- Market events impacting the use of key current therapies in multiple myeloma
- Key results from select clinical trials investigating thalomid / thalidomide / thaled for the treatment of multiple myeloma
- Expert insights: thalomid / thalidomide / thaled
- Key results from select clinical trials investigating lenalidomide for the treatment of multiple myeloma
- Ongoing clinical development of lenalidomide
- Key ongoing clinical trials of lenalidomide in the treatment of multiple myeloma
- Expert insights: lenalidomide
- Key results from select clinical trials investigating Pomalyst / Imnovid for the treatment of multiple myeloma
- Ongoing clinical development of Pomalyst / Imnovid
- Key ongoing clinical trials investigating Pomalyst / Imnovid in the treatment of multiple myeloma
- Expert insights: Pomalyst / Imnovid
- Key results from select clinical trials investigating bortezomib for the treatment of multiple myeloma
- Ongoing clinical development of bortezomib
- Key ongoing clinical trials investigating bortezomib in the treatment of multiple myeloma
- Expert insights: bortezomib
- Key results from select clinical trials investigating Kyprolis for the treatment of multiple myeloma
- Ongoing clinical development of Kyprolis
- Key ongoing clinical trials of Kyprolis in the treatment of multiple myeloma
- Expert insights: Kyprolis
- Key results from select clinical trials investigating Ninlaro for the treatment of multiple myeloma
- Ongoing clinical development of Ninlaro
- Key ongoing clinical trials of Ninlaro in the treatment of multiple myeloma
- Expert insights: Ninlaro
- Key results from select clinical trials investigating Farydak for the treatment of multiple myeloma
- Ongoing clinical development of Farydak
- Key ongoing clinical trials investigating Farydak in the treatment of multiple myeloma
- Expert insights: Farydak
- Key results from select clinical trials investigating Empliciti for the treatment of multiple myeloma
- Ongoing clinical development of Empliciti
- Key ongoing clinical trials investigating Empliciti in the treatment of multiple myeloma
- Expert insights: Empliciti
- Key results from select clinical trials investigating Darzalex / Darzalex Faspro for the treatment of multiple myeloma
- Ongoing clinical development of Darzalex / Darzalex Faspro
- Key ongoing clinical trials of Darzalex / Darzalex Faspro in the treatment of multiple myeloma
- Expert insights: Darzalex / Darzalex Faspro
- Sarclisa
- Key results from select clinical trials investigating Sarclisa for the treatment of multiple myeloma
- Ongoing clinical development of Sarclisa
- Key ongoing clinical trials of Sarclisa in the treatment of multiple myeloma
- Expert insights: Sarclisa
- Xpovio / Nexpovio
- Key results from select clinical trials investigating Xpovio / Nexpovio for the treatment of multiple myeloma
- Ongoing clinical development of Xpovio / Nexpovio
- Expert insights: Xpovio / Nexpovio
- Key results from select clinical trials investigating Blenrep for the treatment of multiple myeloma
- Ongoing clinical development of Blenrep
- Key ongoing clinical trials of Blenrep in the treatment of multiple myeloma
- Expert insights: Blenrep
- Key results from select clinical trials investigating Pepaxto for the treatment of multiple myeloma
- Ongoing clinical development of Pepaxto
- Key ongoing clinical trials of Pepaxto in the treatment of multiple myeloma
- Expert insights: Pepaxto (melflufen)
- Key results from select clinical trials investigating Abecma for the treatment of multiple myeloma
- Ongoing clinical development of Abecma
- Key ongoing clinical trials of Abecma in the treatment of multiple myeloma
- Expert insights: Abecma
- Key results from select clinical trials investigating Carvykti for the treatment of multiple myeloma
- Analysis of the clinical development program for Carvykti
- Key ongoing clinical trials investigating Carvykti in the treatment of multiple myeloma
- Expert insights: Carvykti
- Medical practice
- Asymptomatic multiple myeloma
- First-line transplant-eligible multiple myeloma
- First-line transplant-ineligible multiple myeloma
- Relapsed / refractory multiple myeloma
- Patient characteristics influencing drug selection in multiple myeloma
- Treatment decision tree for multiple myeloma: United States
- Treatment decision tree for multiple myeloma: Europe
- Treatment decision tree for multiple myeloma: Japan
- Key findings
- Unmet Need Overview
- Attainment of Unmet Needs
- Current and Future Attainment of Unmet Needs in Multiple Myeloma
- Top Unmet Needs in Multiple Myeloma: Current and Future Attainment
- Attainment of Unmet Needs
- Emerging Therapies
- Key Findings
- Key Emerging Therapies
- Key Therapies in Development for Multiple Myeloma
- Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Multiple Myeloma
- Key Results From Select Clinical Trials Investigating Venclexta / Venclyxto for the Treatment of Multiple Myeloma
- Key Ongoing Clinical Trials of Venclexta / Venclyxto in the Treatment of Multiple Myeloma
- Analysis of the Clinical Development Program for Venclexta / Venclyxto
- Expert Insights: Venclexta / Venclyxto
- Expectations for Market Authorization and Sales Opportunity of Venclexta / Venclyxto in Multiple Myeloma
- Key Results From Select Clinical Trials Investigating Elranatamab (PF-06863135) for the Treatment of Multiple Myeloma
- Analysis of the Clinical Development Program for Elranatamab
- Key Ongoing Clinical Trials Investigating Elranatamab in the Treatment of Multiple Myeloma
- Expectations for Launch and Sales Opportunity of Elranatamab in Multiple Myeloma
- Teclistamab
- Key Results From Select Clinical Trials Investigating Teclistamab for the Treatment of Multiple Myeloma
- Analysis of the Clinical Development Program for Teclistamab
- Key Ongoing Clinical Trials Investigating Teclistamab in the Treatment of Multiple Myeloma
- Expectations for Launch and Sales Opportunity of Teclistamab in Multiple Myeloma
- Early-Phase Pipeline Analysis
- Select Compounds in Early-Phase Development for Multiple Myeloma
- Key Findings
- Access and Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Multiple Myeloma: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Multiple Myeloma: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Multiple Myeloma: Japan
- General Reimbursement Environment: Japan
- Region-Specific Reimbursement Practices
- Appendix
- Key Abbreviations Related to Multiple Myeloma
- Multiple Myeloma Bibliography
- Key updates
Elliott Puttock, M.Res., Ph.D., is an analyst on the Oncology team at Clarivate. He has experience working in the pharmaceutical sector developing novel therapeutics for ongoing oncology projects. While earning his Ph.D., he specialized in metastatic ovarian cancer and focused on targeting the extracellular matrix to develop new treatments for patients. He obtained his doctorate from Barts Cancer Institute in London.
Ullas Ulahannan, M.P.H., is an associate epidemiologist at Clarivate. Previously, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. He earned a B.S. in nursing from Rajiv Gandhi University and an M.P.H. from Manipal University.